Michelle Petri, MD
Rheumatology · Baltimore, MDNPI 1548206683
Payments from drug & device makers
Across 285 payments — averaging $3706.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$501K
- Janssen Global Services, LLC$105K
- AstraZeneca$93K
- Astrazeneca UK Limited$92K
- Merck$71K
- Aurinia Pharma U.S., Inc.$49K
- plus $146K from 25 others
Across 16 payments — averaging $1466.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono Research & Development Institute, Inc.$9K
- AbbVie$4K
- Emergent Biosolutions Inc.$3K
- EMD Serono, Inc.$3K
- Amgen$2K
- Sanofi US Services Inc.$1K
- plus $1K from 2 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 71 | $500,779 |
| Janssen Global Services, LLC | 3 | $104,600 |
| AstraZeneca(2 entities) | 40 | $92,739 |
| Astrazeneca UK Limited | 9 | $92,092 |
| Merck | 8 | $71,027 |
| Aurinia Pharma U.S., Inc. | 33 | $49,072 |
| Eli Lilly | 33 | $36,602 |
| Sanofi-aventis U.S. LLC | 7 | $29,217 |
| UCB SA | 6 | $14,910 |
| Amgen | 14 | $9,336 |
| Janssen Research & Development, LLC | 7 | $9,330 |
| E.r. Squibb & Sons, L.L.C. | 4 | $6,725 |
| EMD Serono Research & Development Institute, Inc. | 4 | $5,125 |
| Regeneron | 5 | $4,428 |
| Biogen | 3 | $4,187 |
| UCB, Inc. | 1 | $3,540 |
| EMD Serono, Inc. | 2 | $3,000 |
| Sanofi US Services Inc. | 1 | $2,720 |
| Emergent Biosolutions Inc. | 4 | $2,610 |
| Autolus Inc | 3 | $2,591 |
| AbbVie | 9 | $2,143 |
| Phadia GmbH | 2 | $1,940 |
| Inova Diagnostics, Inc. | 1 | $1,400 |
| Astellas Pharma Inc | 2 | $1,288 |
| Bavarian Nordic A/s | 2 | $990 |
| UCB GmbH | 1 | $900 |
| Novartis | 5 | $884 |
| Boehringer Ingelheim | 2 | $645 |
| Biocryst Pharmaceuticals, Inc. | 1 | $595 |
| Orphai Therapeutics Inc. | 1 | $500 |
| Vertex | 1 | $442 |
How this compares
$1,056,357 in reported general payments places this provider in the 95th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Baltimore
- Thomas Grader BeckBaltimore$1.2M
- Laura HummersBaltimore$1M
- Lisa ChristopherBaltimore$370K
- Violeta RusBaltimore$358K
- Ami ShahBaltimore$347K
- Alan BaerBaltimore$277K
- Clifton BinghamBaltimore$210K
- Homa TimlinBaltimore$152K
- Marc HochbergBaltimore$140K
- Philip SeoBaltimore$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.